Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Avidity Biosciences Inc 10578 SCIENCE CENTER DRIVE SUITE 125 SAN DIEGO CA 92121 USA

www.aviditybiosciences.com Employees: 391 P: 858-401-7900

Sector:

Medical

Description:

Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.

Key Statistics

Overview:

Market Capitalization, $K 10,904,422
Enterprise Value, $K 10,684,552
Shares Outstanding, K 150,676
Annual Sales, $ 10,900 K
Annual Net Income, $ -322,300 K
Last Quarter Sales, $ 12,480 K
Last Quarter Net Income, $ -174,440 K
EBIT, $ -612,460 K
EBITDA, $ -631,130 K
60-Month Beta 0.95
% of Insider Shareholders 3.83%
Float, K 144,905
% Float 96.17%
Short Interest 9,740
Short Float 6.46%
Short Volume Ratio 0.26

Growth:

1-Year Return 141.80%
3-Year Return 219.51%
5-Year Return 173.51%
5-Year Revenue Growth 369.83%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.27 on 11/10/25
Next Earnings Date 02/26/26
Earnings Per Share ttm -4.18
EPS Growth vs. Prev Qtr -4.96%
EPS Growth vs. Prev Year -95.38%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

RNA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -37.70%
Return-on-Assets % -33.70%
Profit Margin % -2,956.88%
Debt/Equity 0.00
Price/Sales 455.58
Price/Cash Flow N/A
Price/Book 5.60
Book Value/Share 12.93
Interest Coverage -2.74
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar